FindTrial
Sign In

Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas: An international multicenter cohort study

A multicenter retrospective study of the role of adjuvant therapy in resected invasive intraductal papillary mucinous neoplasm of the pancreas

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008256
Enrollment
290
Registered
2023-03-06
Start date
2021-01-01
Completion date
Unknown
Last updated
2023-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Yonsei University Health System, Severance Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who underwent surgery between 2001.01.01 and 2019.08.01 2. All patients who underwent surgery for the treatment of invasive intraductal papillary mucinous tumor 3. Patients who have been followed up for more than 12 months after surgery 4. Patients with available imaging, pathological, and surgical data

Exclusion criteria

Exclusion criteria: Patients with distant metastasis or unresectable invasive intraductal papillary mucinous tumor confirmed during surgery (Palliative surgery)

Design outcomes

Primary

MeasureTime frame
recurrence;Overall survival—

Secondary

MeasureTime frame
Disease free survival—

Countries

Korea, Republic of

Contacts

Public ContactMunseok Choi

Yonsei University Yongin Severance Hospital

cms2598@yuhs.ac+82-2-2228-2135

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026